• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环肿瘤DNA作为一种用于癌症诊断的新型且有前景的方法：聚焦于肝细胞癌

ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma.

作者信息

Biglari Negin, Soltani-Zangbar Mohammad Sadegh, Mohammadian Jamal, Mehdizadeh Amir, Abbasi Khadijeh

机构信息

Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

EXCLI J. 2023 Aug 3;22:752-780. doi: 10.17179/excli2023-6277. eCollection 2023.

DOI:10.17179/excli2023-6277
PMID:37720239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10502204/
Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent forms of cancer worldwide. Therefore, it is essential to diagnose and treat HCC patients promptly. As a novel discovery, circulating tumor DNA (ctDNA) can be used to analyze the tumor type and the cancer location. Additionally, ctDNA assists the cancer stage determination, which enables medical professionals to provide patients with the most appropriate treatment. This review will discuss the HCC-related mutated genes diagnosed by ctDNA. In addition, we will introduce the different and the most appropriate ctDNA diagnosis approaches based on the facilities.

摘要

肝细胞癌（HCC）是全球最常见的癌症形式之一。因此，及时诊断和治疗HCC患者至关重要。作为一项新发现，循环肿瘤DNA（ctDNA）可用于分析肿瘤类型和癌症位置。此外，ctDNA有助于癌症分期的确定，这使医学专业人员能够为患者提供最合适的治疗。本综述将讨论通过ctDNA诊断的与HCC相关的突变基因。此外，我们将介绍基于现有设备的不同且最合适的ctDNA诊断方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/aac2b7afc947/EXCLI-22-752-g-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/345f306f8b39/EXCLI-22-752-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/06a19478cde9/EXCLI-22-752-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/e11b03865259/EXCLI-22-752-g-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/aac2b7afc947/EXCLI-22-752-g-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/345f306f8b39/EXCLI-22-752-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/06a19478cde9/EXCLI-22-752-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/e11b03865259/EXCLI-22-752-g-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2769/10502204/aac2b7afc947/EXCLI-22-752-g-003.jpg

相似文献

1
ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma.循环肿瘤DNA作为一种用于癌症诊断的新型且有前景的方法：聚焦于肝细胞癌
EXCLI J. 2023 Aug 3;22:752-780. doi: 10.17179/excli2023-6277. eCollection 2023.
2
The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.ctDNA 测序在肝细胞癌中的潜力、分析与展望。
PeerJ. 2022 May 17;10:e13473. doi: 10.7717/peerj.13473. eCollection 2022.
3
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.循环游离肿瘤 DNA 突变作为肝细胞癌生物标志物的鉴定。
Eur J Cancer. 2019 Jul;116:56-66. doi: 10.1016/j.ejca.2019.04.014. Epub 2019 Jun 4.
4
Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.联合组织和循环肿瘤 DNA 可提高肝细胞癌中 CTNNB1 突变的检测率。
BMC Cancer. 2021 Apr 8;21(1):376. doi: 10.1186/s12885-021-08103-0.
5
The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.ctDNA 在肝细胞癌诊断和监测中的应用——文献综述。
Int J Mol Sci. 2023 May 26;24(11):9342. doi: 10.3390/ijms24119342.
6
Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.液体活检利用游离或循环肿瘤 DNA 于肝细胞癌的管理。
Cell Mol Gastroenterol Hepatol. 2022;13(6):1611-1624. doi: 10.1016/j.jcmgh.2022.02.008. Epub 2022 Feb 17.
7
Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.肝细胞癌患者配对循环肿瘤DNA和循环肿瘤细胞中致癌突变的检测
Transl Oncol. 2021 Jul;14(7):101073. doi: 10.1016/j.tranon.2021.101073. Epub 2021 Apr 26.
8
Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.循环肿瘤 DNA/循环肿瘤细胞及其在不同病因诱导的肝细胞癌中的适用性。
Curr Probl Cancer. 2020 Apr;44(2):100516. doi: 10.1016/j.currproblcancer.2019.100516. Epub 2019 Nov 18.
9
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.术前血清 ctDNA 可预测肝细胞癌早期复发和对系统治疗的反应。
Hepatol Int. 2022 Aug;16(4):868-878. doi: 10.1007/s12072-022-10348-1. Epub 2022 Jun 8.
10
Circulating tumor DNA in hepatocellular carcinoma: trends and challenges.肝细胞癌中的循环肿瘤DNA：趋势与挑战
Cell Biosci. 2016 May 11;6:32. doi: 10.1186/s13578-016-0100-z. eCollection 2016.

引用本文的文献

1
Updates on Liquid Biopsy and ctDNA in Transplant Oncology.移植肿瘤学中液体活检与循环肿瘤DNA的最新进展
Cancers (Basel). 2025 Jun 10;17(12):1930. doi: 10.3390/cancers17121930.
2
A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors.胃肠道肿瘤免疫治疗的全面综述，重点关注与PARP抑制剂联合治疗的作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 9. doi: 10.1007/s00210-025-04336-z.
3
Recent advances in ctDNA detection using electrochemical biosensor for cancer.

本文引用的文献

1
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.循环游离DNA分析可预测接受联合免疫治疗的晚期肝细胞癌患者的治疗结果。
Cancers (Basel). 2022 Jul 11;14(14):3367. doi: 10.3390/cancers14143367.
2
Circulating cell-free DNA for cancer early detection.用于癌症早期检测的循环游离DNA
Innovation (Camb). 2022 May 6;3(4):100259. doi: 10.1016/j.xinn.2022.100259. eCollection 2022 Jul 12.
3
Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma.
使用电化学生物传感器检测癌症患者循环肿瘤DNA的研究进展
Discov Oncol. 2024 Oct 2;15(1):517. doi: 10.1007/s12672-024-01365-7.
4
Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review).液体活检：循环肿瘤DNA综述（综述）
Oncol Lett. 2024 Sep 13;28(5):548. doi: 10.3892/ol.2024.14681. eCollection 2024 Nov.
液体活检在肝细胞癌中的临床应用
Front Oncol. 2022 Feb 8;12:781820. doi: 10.3389/fonc.2022.781820. eCollection 2022.
4
Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.液体活检利用游离或循环肿瘤 DNA 于肝细胞癌的管理。
Cell Mol Gastroenterol Hepatol. 2022;13(6):1611-1624. doi: 10.1016/j.jcmgh.2022.02.008. Epub 2022 Feb 17.
5
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.循环肿瘤DNA分析与功能成像为转移性黑色素瘤的全面疾病监测提供了互补方法。
JCO Precis Oncol. 2017 Nov;1:1-14. doi: 10.1200/PO.16.00009.
6
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.实体瘤中的循环肿瘤DNA与微小残留病（MRD）：当前视野与未来展望
Front Oncol. 2021 Nov 18;11:763790. doi: 10.3389/fonc.2021.763790. eCollection 2021.
7
Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways.Wnt/β-连环蛋白信号通路作为肝细胞癌进展的驱动因素：着重于分子途径
J Hepatocell Carcinoma. 2021 Nov 25;8:1415-1444. doi: 10.2147/JHC.S336858. eCollection 2021.
8
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma.循环游离DNA在肝细胞癌中的临床应用价值
Front Mol Biosci. 2021 Sep 29;8:736330. doi: 10.3389/fmolb.2021.736330. eCollection 2021.
9
An Overview of the Genomic Characterization of Hepatocellular Carcinoma.肝细胞癌的基因组特征概述
J Hepatocell Carcinoma. 2021 Sep 7;8:1077-1088. doi: 10.2147/JHC.S270533. eCollection 2021.
10
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.全基因组测序有助于急性淋巴细胞白血病、神经母细胞瘤和尤文肉瘤患者特异性基于定量 PCR 的微小残留病监测。
Br J Cancer. 2022 Feb;126(3):482-491. doi: 10.1038/s41416-021-01538-z. Epub 2021 Sep 1.